Sign Up to like & get
recommendations!
0
Published in 2017 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000000395
Abstract: Background: Vorapaxar, a novel antiplatelet thrombin PAR-1 inhibitor, is currently approved for post myocardial infarction and peripheral artery disease indications with concomitant use of clopidogrel and/or aspirin. The vorapaxar safety profile was acceptable. However, aside…
read more here.
Keywords:
adverse association;
association vorapaxar;
vorapaxar;
association ... See more keywords